Lewy body disease and dementia: A review

Archives of Internal Medicine

Volumn 156, Issue 5, 1996, Pages 487-493

  Kalra, Sanjay ^a   Bergeron, Catherine ^a   Lang, Anthony E ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT; ONDANSETRON; SEROTONIN ANTAGONIST; TACRINE;

ALZHEIMER DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; EXTRAPYRAMIDAL SYMPTOM; HISTOPATHOLOGY; HUMAN; LEWY BODY; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 0029930181     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.5.487     Document Type: Review

References (62)

1. Larson EB, Kukull WA, Katzman RL. Cognitive impairment dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449.
2. Aronson MK, Ooi WL, Geva DL, Masur D Dementia: age-dependent incidence, prevalence, and mortality in the old. Arch Intern Med. 1991,151: 989-992.
3. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1994
5. Cummings JL. Dementia: A Clinical Approach 2nd ed. Stoneham, Mass: Butterworth Publishers Inc, 1992
6. Tolsa ES, Alvarez R. Differential diagnosis of cortical vs subcortacal dementing disorders. Acta Neurol Scand. 1992,139(suppl):47-53.
7. Clarfield AM The reversible dementias: do they reverse? Ann Intern Med. 1988;109:476-486.
8. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis of evaluation of dementia (summary statement). Neurology. 1994;44:2203-2206.
9. Lewy FH. Paralysis agitans, I: Pathologiche Anatomie In: Lewandowsky M, ed. Handbuch der Neurologie. New York, NY: Springer Publishing Co Inc; 1912:920-933.
10. Pollanen MS, Bergeron C, Weyer L Detergent-insoluble cortical Lewy body fibrils share epitopes with neurofilament and r. J Neurochem. 1992;58:1953-1956.
11. Pollanen MS, Bergeron C, Weyer L. Deposition of detergent-resistant neurofilaments into Lewy body fibrils Brain Res. 1993;603:121-124.
12. Dickson DW, Crystal H, Mattiace LA, et al. Ditfuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 1989,78:572-584.
13. Kuzuhara S, Mori H, Izumiyama N, Yashimura M, Ihara Y. Lewy bodies are ubiquitinated. Acta Neuropathol (Berl). 1988;75:345-353
14. Forno LS. The Lewy body in Parkinson's disease. Adv Neurol. 1936;45:35-43.
15. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol. 1993,52:183-191.
16. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease? Clin Neuropathol. 1984;3 185-192.
17. Yoshimura M. Cortical changes in the parkinsonian brain: a contribution to the delineation of 'diffuse Lewy body disease.' J Neurol. 1983;229: 17-32.
18. Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989.52.67-71.
19. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol. 1961;20:237-244.
20. Gibb WR, Luthert PJ, Janota I, Lantos PL Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry. 1989;52:185-192.
21. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990;237:197-204.
22. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type, a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci. 1990; 95:119-139.
23. Hansen L, Salmon O, Galasko D, et al. The Lewy body variant of Alzheimer's disease a clinical and pathologic entity. Neurology. 1990;40:1-8.
24. De la Monte SM, Wells SE, Hedley-Whyte ET, Growdon JH. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neurol. 1989;26 309-320.
25. Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease, correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry. 1989;52:1236-1247.
26. Dickson DW, Ruan D, Crystal H, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD Neurology, 1991;41:1402-1409.
27. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
28. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy body disease and progressive dementia. Neurology. 1988,38:1520-1528.
29. Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease clinical and pathological findings. Br J Psychiatry. 1993;162:385-392.
30. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry. 1989; 52:709-717
31. Louis ED, Goldman JE, Powers JM, Fahn S. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease Mov Disord. 1995;10:188-194.
32. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology. 1990;40:1523-1528.
33. McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT) Br J Psychiatry 1994;165:324-332.
34. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992; 305:673-678.
35. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and interrater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology. 1994;44:872-877
36. Mega MS, Masterman D, Vinters H, et al. Diffuse Lewy body disease a clinical-pathologic study. Neurology. 1995;45(suppl 4):A240. Abstract.
37. Robinson DJ, Merskey H, Blume WT, Fry R, Williamson PC, Hackinski VC. Electroencephalography as an aid in the exclusion of Alzheimer's disease. Arch Neurol. 1994;51:280-284.
38. Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990,40:832-834.
39. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease Mov Disord. 1992,7:125-131.
40. Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5:206-208.
41. Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-749.
42. Levy R, Sahakian B. Alzheimer's disease and Lewy body dementia. Br J Psychiatry. 1994;164:268.
43. Wilcock GK, Scott M. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 1994; 344:544
44. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist Neurology. 1995;45:1305-1308.
45. Kosaka K. Dementia and neuropathology in Lewy body disease. Adv Neurol 1993;60:456-463.
46. Levin BE, Tomer R, Rey GJ. Cognitive impairments in Parkinson's disease. Neurol Clin. 1992; 10:471-484.
47. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med. 1992; 22:911-922.
48. Strittmatter WJ, Saunders AM, Schmechel D, et al Apolipoprolein E: high affinity binding to β-amyloid increased frequency of type 4 allele in familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
49. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923
50. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
51. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342:697-699.
52. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein ε4 allele in patients with Alzheimer's disease Ann Neurol. 1993;34:752-754.
53. Brousseau T, Legrain S, Berr C, Groulet V, Vidai O. Amouyel P. Confirmation of the ε4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994,44: 342-344.
54. Galasko D, Saitoh T, Xia Y, et al. The apolipoprotein E allele ε4 is overrepresented in patients with the Lewy body variant of Aizheimer's disease. Neurology. 1994;44:1950-1951.
55. Arai H, Higuchi S, Muramatsu T, Iwatsubo T, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease. Lancet. 1994;334: 1307.
56. Lippa CF, Smith TW, Saunders AM, et at. Apolipoprotein E genotype and Lewy body disease. Neurology. 1995;45:97-103.
57. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol. 1995; 37:110-112.
58. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339: 1017-1018.
59. Kondo I, Kanazawa I Debrisoquine hydroxylase and Parkinson's disease. Adv Neurol 1993;60: 338-342.
60. 450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48 166-168.
61. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease Lancet. 1992; 339:1375-1377.
62. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics. 1991;1:33-41.